| 1 | 1 | | I |
|---|
| 2 | 2 | | 118THCONGRESS |
|---|
| 3 | 3 | | 1 |
|---|
| 4 | 4 | | STSESSION H. R. 238 |
|---|
| 5 | 5 | | To amend the Omnibus Crime Control and Safe Streets Act of 1968 to |
|---|
| 6 | 6 | | reauthorize the residential substance use disorder treatment program, |
|---|
| 7 | 7 | | and for other purposes. |
|---|
| 8 | 8 | | IN THE HOUSE OF REPRESENTATIVES |
|---|
| 9 | 9 | | JANUARY10, 2023 |
|---|
| 10 | 10 | | Ms. J |
|---|
| 11 | 11 | | ACKSONLEEintroduced the following bill; which was referred to the |
|---|
| 12 | 12 | | Committee on the Judiciary |
|---|
| 13 | 13 | | A BILL |
|---|
| 14 | 14 | | To amend the Omnibus Crime Control and Safe Streets |
|---|
| 15 | 15 | | Act of 1968 to reauthorize the residential substance use |
|---|
| 16 | 16 | | disorder treatment program, and for other purposes. |
|---|
| 17 | 17 | | Be it enacted by the Senate and House of Representa-1 |
|---|
| 18 | 18 | | tives of the United States of America in Congress assembled, 2 |
|---|
| 19 | 19 | | SECTION 1. SHORT TITLE. 3 |
|---|
| 20 | 20 | | This Act may be cited as the ‘‘Residential Substance 4 |
|---|
| 21 | 21 | | Use Disorder Treatment Act of 2023’’. 5 |
|---|
| 22 | 22 | | VerDate Sep 11 2014 00:44 Jan 20, 2023 Jkt 039200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\H238.IH H238 |
|---|
| 23 | 23 | | pbinns on DSKJLVW7X2PROD with $$_JOB 2 |
|---|
| 24 | 24 | | •HR 238 IH |
|---|
| 25 | 25 | | SEC. 2. RESIDENTIAL SUBSTANCE USE DISORDER TREAT-1 |
|---|
| 26 | 26 | | MENT PROGRAM. 2 |
|---|
| 27 | 27 | | (a) A |
|---|
| 28 | 28 | | MENDMENTS.—Part S of title I of the Omnibus 3 |
|---|
| 29 | 29 | | Crime Control and Safe Streets Act of 1968 (34 U.S.C. 4 |
|---|
| 30 | 30 | | 10421 et seq.) is amended— 5 |
|---|
| 31 | 31 | | (1) in the part heading, by striking ‘‘ |
|---|
| 32 | 32 | | SUB-6 |
|---|
| 33 | 33 | | STANCE ABUSE ’’ and inserting ‘‘SUBSTANCE USE 7 |
|---|
| 34 | 34 | | DISORDER’’; 8 |
|---|
| 35 | 35 | | (2) in section 1901 (34 U.S.C. 10421)— 9 |
|---|
| 36 | 36 | | (A) in subsection (a)— 10 |
|---|
| 37 | 37 | | (i) in paragraph (1)— 11 |
|---|
| 38 | 38 | | (I) by striking ‘‘substance abuse’’ 12 |
|---|
| 39 | 39 | | each place it appears and inserting 13 |
|---|
| 40 | 40 | | ‘‘substance use disorder’’; and 14 |
|---|
| 41 | 41 | | (II) by inserting after ‘‘pro-15 |
|---|
| 42 | 42 | | grams’’ the following: ‘‘, including 16 |
|---|
| 43 | 43 | | medication-assisted treatment pro-17 |
|---|
| 44 | 44 | | grams, which shall be permitted to 18 |
|---|
| 45 | 45 | | use any type of medication that has 19 |
|---|
| 46 | 46 | | been approved to treat substance use 20 |
|---|
| 47 | 47 | | disorders pursuant to section 505 of 21 |
|---|
| 48 | 48 | | the Federal Food, Drug, and Cos-22 |
|---|
| 49 | 49 | | metic Act (21 U.S.C. 355), or any 23 |
|---|
| 50 | 50 | | type of biological product licensed 24 |
|---|
| 51 | 51 | | under section 351 of the Public 25 |
|---|
| 52 | 52 | | VerDate Sep 11 2014 00:44 Jan 20, 2023 Jkt 039200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\H238.IH H238 |
|---|
| 53 | 53 | | pbinns on DSKJLVW7X2PROD with $$_JOB 3 |
|---|
| 54 | 54 | | •HR 238 IH |
|---|
| 55 | 55 | | Health Service Act (42 U.S.C. 262),’’; 1 |
|---|
| 56 | 56 | | and 2 |
|---|
| 57 | 57 | | (ii) in paragraph (3), by striking 3 |
|---|
| 58 | 58 | | ‘‘substance abuse’’ each place it appears 4 |
|---|
| 59 | 59 | | and inserting ‘‘substance use disorder’’; 5 |
|---|
| 60 | 60 | | (B) in subsection (b), by striking ‘‘sub-6 |
|---|
| 61 | 61 | | stance abuse’’ and inserting ‘‘substance use dis-7 |
|---|
| 62 | 62 | | order’’; and 8 |
|---|
| 63 | 63 | | (C) in subsection (c)— 9 |
|---|
| 64 | 64 | | (i) by striking ‘‘part for treatment’’ 10 |
|---|
| 65 | 65 | | and inserting ‘‘part for— 11 |
|---|
| 66 | 66 | | ‘‘(1) treatment’’; 12 |
|---|
| 67 | 67 | | (ii) in paragraph (1), as so des-13 |
|---|
| 68 | 68 | | ignated, by striking the period at the end 14 |
|---|
| 69 | 69 | | and inserting ‘‘; and’’; and 15 |
|---|
| 70 | 70 | | (iii) by adding at the end the fol-16 |
|---|
| 71 | 71 | | lowing: 17 |
|---|
| 72 | 72 | | ‘‘(2) expanding residential substance use dis-18 |
|---|
| 73 | 73 | | order treatment programs to use not less than 1 19 |
|---|
| 74 | 74 | | medication or treatment that has been approved to 20 |
|---|
| 75 | 75 | | treat substance use disorders pursuant to section 21 |
|---|
| 76 | 76 | | 505 of the Federal Food, Drug, and Cosmetic Act 22 |
|---|
| 77 | 77 | | (21 U.S.C. 355).’’; 23 |
|---|
| 78 | 78 | | (3) in section 1902 (34 U.S.C. 10422)— 24 |
|---|
| 79 | 79 | | (A) in subsection (b)— 25 |
|---|
| 80 | 80 | | VerDate Sep 11 2014 00:44 Jan 20, 2023 Jkt 039200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6201 E:\BILLS\H238.IH H238 |
|---|
| 81 | 81 | | pbinns on DSKJLVW7X2PROD with $$_JOB 4 |
|---|
| 82 | 82 | | •HR 238 IH |
|---|
| 83 | 83 | | (i) in the subsection heading, by strik-1 |
|---|
| 84 | 84 | | ing ‘‘A |
|---|
| 85 | 85 | | BUSE’’ and inserting ‘‘USE’’; and 2 |
|---|
| 86 | 86 | | (ii) by striking ‘‘substance abuse’’ 3 |
|---|
| 87 | 87 | | each place it appears and inserting ‘‘sub-4 |
|---|
| 88 | 88 | | stance use disorder’’; 5 |
|---|
| 89 | 89 | | (B) in subsection (c), by striking ‘‘sub-6 |
|---|
| 90 | 90 | | stance abuse’’ each place it appears and insert-7 |
|---|
| 91 | 91 | | ing ‘‘substance use disorder’’; 8 |
|---|
| 92 | 92 | | (C) in subsection (d), by striking ‘‘sub-9 |
|---|
| 93 | 93 | | stance abuse treatment’’ and inserting ‘‘sub-10 |
|---|
| 94 | 94 | | stance use disorder treatment’’; 11 |
|---|
| 95 | 95 | | (D) in subsection (f), by striking ‘‘sub-12 |
|---|
| 96 | 96 | | stance abuse’’ and inserting ‘‘substance use dis-13 |
|---|
| 97 | 97 | | order’’; and 14 |
|---|
| 98 | 98 | | (E) by adding at the end the following: 15 |
|---|
| 99 | 99 | | ‘‘(g) T |
|---|
| 100 | 100 | | RAININGREQUIREMENT.— 16 |
|---|
| 101 | 101 | | ‘‘(1) I |
|---|
| 102 | 102 | | N GENERAL.—To be eligible to receive 17 |
|---|
| 103 | 103 | | funds under this part, the chief medical officer of 18 |
|---|
| 104 | 104 | | the prison or jail or appropriate staff overseeing the 19 |
|---|
| 105 | 105 | | program shall complete training, before or within a 20 |
|---|
| 106 | 106 | | reasonable amount of time after receiving the funds, 21 |
|---|
| 107 | 107 | | on, at a minimum— 22 |
|---|
| 108 | 108 | | ‘‘(A) the science of addiction; 23 |
|---|
| 109 | 109 | | ‘‘(B) the latest research and clinical guid-24 |
|---|
| 110 | 110 | | ance for detoxification and withdrawal manage-25 |
|---|
| 111 | 111 | | VerDate Sep 11 2014 00:44 Jan 20, 2023 Jkt 039200 PO 00000 Frm 00004 Fmt 6652 Sfmt 6201 E:\BILLS\H238.IH H238 |
|---|
| 112 | 112 | | pbinns on DSKJLVW7X2PROD with $$_JOB 5 |
|---|
| 113 | 113 | | •HR 238 IH |
|---|
| 114 | 114 | | ment and the treatment of substance use dis-1 |
|---|
| 115 | 115 | | orders in criminal justice settings; 2 |
|---|
| 116 | 116 | | ‘‘(C) strategies for continuity of care dur-3 |
|---|
| 117 | 117 | | ing and after incarceration; 4 |
|---|
| 118 | 118 | | ‘‘(D) an overview of— 5 |
|---|
| 119 | 119 | | ‘‘(i) all medications for the treatment 6 |
|---|
| 120 | 120 | | of substance use disorders; 7 |
|---|
| 121 | 121 | | ‘‘(ii) how to obtain certification as an 8 |
|---|
| 122 | 122 | | opioid treatment provider (OTP) or waiv-9 |
|---|
| 123 | 123 | | ers under the Controlled Substances Act 10 |
|---|
| 124 | 124 | | (21 U.S.C. 801 et seq.) for prescribing cer-11 |
|---|
| 125 | 125 | | tain medications; and 12 |
|---|
| 126 | 126 | | ‘‘(iii) evidence-based behavioral thera-13 |
|---|
| 127 | 127 | | pies used in addition to medication to im-14 |
|---|
| 128 | 128 | | prove medication adherence and treatment 15 |
|---|
| 129 | 129 | | outcomes; and 16 |
|---|
| 130 | 130 | | ‘‘(E) any other topic determined by the At-17 |
|---|
| 131 | 131 | | torney General, in coordination with the Sec-18 |
|---|
| 132 | 132 | | retary of Health and Human Services and in 19 |
|---|
| 133 | 133 | | consultation with experts in addiction science, 20 |
|---|
| 134 | 134 | | to be a core element for successful training 21 |
|---|
| 135 | 135 | | under this paragraph. 22 |
|---|
| 136 | 136 | | ‘‘(2) R |
|---|
| 137 | 137 | | EQUIREMENT.—The training required 23 |
|---|
| 138 | 138 | | under paragraph (1) shall include guidance on how 24 |
|---|
| 139 | 139 | | to— 25 |
|---|
| 140 | 140 | | VerDate Sep 11 2014 00:44 Jan 20, 2023 Jkt 039200 PO 00000 Frm 00005 Fmt 6652 Sfmt 6201 E:\BILLS\H238.IH H238 |
|---|
| 141 | 141 | | pbinns on DSKJLVW7X2PROD with $$_JOB 6 |
|---|
| 142 | 142 | | •HR 238 IH |
|---|
| 143 | 143 | | ‘‘(A) engage relevant stakeholders; 1 |
|---|
| 144 | 144 | | ‘‘(B) identify available resources for, and 2 |
|---|
| 145 | 145 | | gaps and barriers to, providing residential sub-3 |
|---|
| 146 | 146 | | stance use disorder treatment; and 4 |
|---|
| 147 | 147 | | ‘‘(C) develop a plan to overcome obstacles 5 |
|---|
| 148 | 148 | | to administering and offering medication-as-6 |
|---|
| 149 | 149 | | sisted treatment. 7 |
|---|
| 150 | 150 | | ‘‘(h) P |
|---|
| 151 | 151 | | ROVIDERAFFILIATION.—Any entity, including 8 |
|---|
| 152 | 152 | | a prison or jail, that receives Federal funds for a program 9 |
|---|
| 153 | 153 | | or activity that offers medication-assisted treatment shall 10 |
|---|
| 154 | 154 | | have an affiliation with a provider that can— 11 |
|---|
| 155 | 155 | | ‘‘(1) prescribe not less than 1 medication-as-12 |
|---|
| 156 | 156 | | sisted treatment to patients after release from the 13 |
|---|
| 157 | 157 | | entity; and 14 |
|---|
| 158 | 158 | | ‘‘(2) discuss the risks and benefits of, and alter-15 |
|---|
| 159 | 159 | | natives to, medication-assisted treatment with pa-16 |
|---|
| 160 | 160 | | tients.’’; and 17 |
|---|
| 161 | 161 | | (4) in section 1904 (34 U.S.C. 10424)— 18 |
|---|
| 162 | 162 | | (A) by amending subsection (c) to read as 19 |
|---|
| 163 | 163 | | follows: 20 |
|---|
| 164 | 164 | | ‘‘(c) L |
|---|
| 165 | 165 | | OCALALLOCATION.— 21 |
|---|
| 166 | 166 | | ‘‘(1) I |
|---|
| 167 | 167 | | N GENERAL.—Not less than 10 percent of 22 |
|---|
| 168 | 168 | | the total amount made available to a State under 23 |
|---|
| 169 | 169 | | subsection (a) for any fiscal year shall be used by 24 |
|---|
| 170 | 170 | | the State to make grants to local correctional and 25 |
|---|
| 171 | 171 | | VerDate Sep 11 2014 00:44 Jan 20, 2023 Jkt 039200 PO 00000 Frm 00006 Fmt 6652 Sfmt 6201 E:\BILLS\H238.IH H238 |
|---|
| 172 | 172 | | pbinns on DSKJLVW7X2PROD with $$_JOB 7 |
|---|
| 173 | 173 | | •HR 238 IH |
|---|
| 174 | 174 | | detention facilities in the State (provided such facili-1 |
|---|
| 175 | 175 | | ties exist therein). 2 |
|---|
| 176 | 176 | | ‘‘(2) J |
|---|
| 177 | 177 | | AIL-BASED SUBSTANCE USE TREATMENT 3 |
|---|
| 178 | 178 | | PROGRAMS.—A jail-based substance use disorder 4 |
|---|
| 179 | 179 | | treatment program described in paragraph (1) may 5 |
|---|
| 180 | 180 | | be made available to any individual who is— 6 |
|---|
| 181 | 181 | | ‘‘(A) awaiting trial or is otherwise in pre- 7 |
|---|
| 182 | 182 | | trial detention; or 8 |
|---|
| 183 | 183 | | ‘‘(B) serving a sentence of imprisonment in 9 |
|---|
| 184 | 184 | | the jail.’’; and 10 |
|---|
| 185 | 185 | | (B) by amending subsection (d) to read as 11 |
|---|
| 186 | 186 | | follows: 12 |
|---|
| 187 | 187 | | ‘‘(d) E |
|---|
| 188 | 188 | | VIDENCE-BASEDTREATMENTS.— 13 |
|---|
| 189 | 189 | | ‘‘(1) I |
|---|
| 190 | 190 | | N GENERAL.—A State may use amounts 14 |
|---|
| 191 | 191 | | received under this part to— 15 |
|---|
| 192 | 192 | | ‘‘(A) provide any type of medication-as-16 |
|---|
| 193 | 193 | | sisted treatment that has been approved to 17 |
|---|
| 194 | 194 | | treat substance use disorders pursuant to sec-18 |
|---|
| 195 | 195 | | tion 505 of the Federal Food, Drug, and Cos-19 |
|---|
| 196 | 196 | | metic Act (21 U.S.C. 355), and any type of bio-20 |
|---|
| 197 | 197 | | logical product licensed under section 351 of 21 |
|---|
| 198 | 198 | | the Public Health Service Act (42 U.S.C. 262), 22 |
|---|
| 199 | 199 | | and prescribe overdose reversal medications 23 |
|---|
| 200 | 200 | | during the residential substance use disorder 24 |
|---|
| 201 | 201 | | treatment program or after care; 25 |
|---|
| 202 | 202 | | VerDate Sep 11 2014 00:44 Jan 20, 2023 Jkt 039200 PO 00000 Frm 00007 Fmt 6652 Sfmt 6201 E:\BILLS\H238.IH H238 |
|---|
| 203 | 203 | | pbinns on DSKJLVW7X2PROD with $$_JOB 8 |
|---|
| 204 | 204 | | •HR 238 IH |
|---|
| 205 | 205 | | ‘‘(B) cover costs associated with the train-1 |
|---|
| 206 | 206 | | ing required under section 1902(g); 2 |
|---|
| 207 | 207 | | ‘‘(C) obtain waivers under clause (ii) or 3 |
|---|
| 208 | 208 | | (iv) of section 303(g)(2)(G) of the Controlled 4 |
|---|
| 209 | 209 | | Substances Act (21 U.S.C. 823(g)(2)(G)); and 5 |
|---|
| 210 | 210 | | ‘‘(D) obtain certification as an opioid 6 |
|---|
| 211 | 211 | | treatment provider (OTP) in accordance with 7 |
|---|
| 212 | 212 | | part 8 of title 42, Code of Federal Regulations, 8 |
|---|
| 213 | 213 | | or any successor thereto, or the prescription of 9 |
|---|
| 214 | 214 | | medications to treat substance use disorders. 10 |
|---|
| 215 | 215 | | ‘‘(2) D |
|---|
| 216 | 216 | | EFINITION.—In this subsection, the term 11 |
|---|
| 217 | 217 | | ‘medication-assisted treatment’ means a treatment 12 |
|---|
| 218 | 218 | | plan that combines behavioral therapy with any type 13 |
|---|
| 219 | 219 | | of medication that has been approved to treat sub-14 |
|---|
| 220 | 220 | | stance use disorders pursuant to section 505 of the 15 |
|---|
| 221 | 221 | | Federal Food, Drug, and Cosmetic Act (21 U.S.C. 16 |
|---|
| 222 | 222 | | 355), or any type of biological product licensed 17 |
|---|
| 223 | 223 | | under section 351 of the Public Health Service Act 18 |
|---|
| 224 | 224 | | (42 U.S.C. 262).’’. 19 |
|---|
| 225 | 225 | | (b) A |
|---|
| 226 | 226 | | UTHORIZATION OF APPROPRIATIONS.—Section 20 |
|---|
| 227 | 227 | | 1001(a)(17) of title I of the Omnibus Crime Control and 21 |
|---|
| 228 | 228 | | Safe Streets Act of 1968 (34 U.S.C. 10261(a)(17)) is 22 |
|---|
| 229 | 229 | | amended to read as follows: 23 |
|---|
| 230 | 230 | | VerDate Sep 11 2014 00:44 Jan 20, 2023 Jkt 039200 PO 00000 Frm 00008 Fmt 6652 Sfmt 6201 E:\BILLS\H238.IH H238 |
|---|
| 231 | 231 | | pbinns on DSKJLVW7X2PROD with $$_JOB 9 |
|---|
| 232 | 232 | | •HR 238 IH |
|---|
| 233 | 233 | | ‘‘(17) There are authorized to be appropriated to 1 |
|---|
| 234 | 234 | | carry out the projects under part S $40,000,000 for each 2 |
|---|
| 235 | 235 | | of fiscal years 2023 through 2027.’’. 3 |
|---|
| 236 | 236 | | (c) D |
|---|
| 237 | 237 | | EFINITION.—Section 901(25) of title I of the 4 |
|---|
| 238 | 238 | | Omnibus Crime Control and Safe Streets Act of 1968 (34 5 |
|---|
| 239 | 239 | | U.S.C. 10251(25)) is amended to read as follows: 6 |
|---|
| 240 | 240 | | ‘‘(25) the term ‘residential substance use dis-7 |
|---|
| 241 | 241 | | order treatment program’ means a course of com-8 |
|---|
| 242 | 242 | | prehensive individual and group substance use dis-9 |
|---|
| 243 | 243 | | order treatment services in residential treatment fa-10 |
|---|
| 244 | 244 | | cilities that, to the greatest extent practicable, follow 11 |
|---|
| 245 | 245 | | the guidance entitled, ‘Promising Practice Guidelines 12 |
|---|
| 246 | 246 | | for Residential Substance Abuse Treatment’, pub-13 |
|---|
| 247 | 247 | | lished in November 2017 by the Bureau of Justice 14 |
|---|
| 248 | 248 | | Assistance, or as thereafter amended to conform to 15 |
|---|
| 249 | 249 | | current standards of care;’’. 16 |
|---|
| 250 | 250 | | Æ |
|---|
| 251 | 251 | | VerDate Sep 11 2014 00:44 Jan 20, 2023 Jkt 039200 PO 00000 Frm 00009 Fmt 6652 Sfmt 6301 E:\BILLS\H238.IH H238 |
|---|
| 252 | 252 | | pbinns on DSKJLVW7X2PROD with $$_JOB |
|---|